Anthony S. Murabito
Corporate Officer/Principal bei New Jersey Society of Health-System Pharmacists
Profil
Anthony S.
Murabito is a professional with current memberships in the New Jersey Society of Health-System Pharmacists and the Pennsylvania Society of Health-System Pharmacists.
He previously worked as the Group Director of Research & Development at GSK Plc from 1981 to 2000, as well as the Chief Information Officer & Vice President at Human Genome Sciences, Inc. and Cubist Pharmaceuticals LLC.
He also served as the VP of Information Technology & Corporate Services at Transkaryotic Therapies, Inc. from 2001 to 2003.
Murabito received his undergraduate degree from the University of the Sciences in Philadelphia and his graduate degree from Widener University.
Aktive Positionen von Anthony S. Murabito
| Unternehmen | Position | Beginn |
|---|---|---|
| New Jersey Society of Health-System Pharmacists | Corporate Officer/Principal | - |
| Pennsylvania Society of Health-System Pharmacists | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Anthony S. Murabito
| Unternehmen | Position | Ende |
|---|---|---|
Transkaryotic Therapies, Inc.
 Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2003 |
| GSK PLC | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2000 |
Human Genome Sciences, Inc.
 Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Technik-/Wissenschafts-/F&E-Leiter | - |
| CUBIST PHARMACEUTICALS INC | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Anthony S. Murabito
| University of the Sciences in Philadelphia | Undergraduate Degree |
| Widener University | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| GSK PLC | Health Technology |
| Private Unternehmen | 5 |
|---|---|
Cubist Pharmaceuticals LLC
 Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA. | Health Technology |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | Commercial Services |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Health Technology |
| New Jersey Society of Health-System Pharmacists | |
| Pennsylvania Society of Health-System Pharmacists |
